GlobeNewswire Inc.··Nicox SaNicox's NCX 470 Achieves Primary Efficacy Endpoints in Phase 3 Glaucoma Trial
Nicox's NCX 470 eye drop met primary efficacy endpoints in Phase 3 glaucoma trials, showing superior IOP reduction versus standard treatment with favorable safety profile.
BLCOPhase 3 clinical trialFDA approval